Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Gumus, M.Kilickap, S.Sezer, A.Bondarenko, I.Ozguroglu, M.Gogishvili, M.He, X.Gullo, G.Rietschel, P.Quek, R. G.2024-04-242024-04-242023http://hdl.handle.net/11727/12038enginfo:eu-repo/semantics/closedAccessCemiplimabAdvancedNSCLCPatient-reported outcomesDisease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1Conference Object1811S321S321001098831600537